Zharp1-163

• Description:

  Zharp1-163 is a dual inhibitor of ferroptosis and necroptosis. Zharp1-163 effectively blocks ferroptosis by reducing reactive oxygen species (ROS) levels and inhibits necroptosis by potently and selectively targeting RIPK1 kinase activity (KD = 240 nM; IC50 = 406.1 nM) . Zharp1-163 inhibits the cellular activation of RIPK1, RIPK3 and MLKL in response to necroptotic stimulation. Zharp1-163 markedly attenuates TNF-α (HY-P1875) -induced systemic inflammatory syndrome, including the prevention of TNF-α-induced mortality and hypothermia in mice. Zharp1-163 significantly alleviates acute kidney injury associated with both necroptosis and ferroptosis in models induced by Cisplatin (HY-17394) and ischemia-reperfusion. Zharp1-163 can be used for the study of diseases associated with cell death pathways, such as kidney disease[1].

• UNSPSC:

  12352005

• Target:

  Ferroptosis; Mixed Lineage Kinase; Necroptosis; Reactive Oxygen Species (ROS) ; RIP kinase

• Related Pathways:

  Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Smiles:

  NC1=CN2C(C=CC(C3=CC4=C(N=C3)OCCN4C(OC5CCCCC5)=O)=C2)=N1

• Molecular Formula:

  C21H23N5O3

• Molecular Weight:

  393.44

• References & Citations:

  [1]Ji Y, et al. Discovery of Zharp1-163 as a dual inhibitor of ferroptosis and necroptosis for the treatment of inflammatory disorders and kidney injury. Cell Death Discov. 2025 Aug 28;11 (1) :413.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  RIPK1; RIPK3